A leader in scientific collaborative research management, Dr. Fasman directed drug development strategy and performance at Astra Zeneca and served as chief scientific offer at the Adelson Medical Research Foundation prior to joining JAX in 2015.
Over the last 15 years Fasman has built many connections with JAX, serving on the Laboratory’s scientific advisory board and advising the Genetic Resource Sciences group. He currently serves on the JAX board of scientific counselors.
Fasman joins the Laboratory from the Adelson Medical Research Foundation in Needham, Mass., where he has been vice president and chief scientific officer since 2008. From 1998 to 2008, he worked with the international pharmaceutical giant AstraZeneca, rising to director of drug development strategy and performance.
From 1992 to 1998, Fasman worked on the human genome project at the Johns Hopkins University School of Medicine and later at the Whitehead Institute/MIT Center for Genome Research. While earning his Ph.D. in biomedical engineering from Hopkins, Fasman co-founded a laboratory software and systems design consulting firm, BME Systems, Inc.
Kenneth Fasman, Ph.D., named new Jackson Laboratory vice president for strategic initiatives